

<b>Reference:</b>	FOI.18076.25
<b>Subject:</b>	Treatment of inflammatory diseases
<b>Date of Request:</b>	13 August 2025

### Your request and our response

I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) for the three-month period specified within the question.

I have provided a grid of drug names and department names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Hywel Dda University Health Board (UHB) provides within the table overleaf, the number of Dermatology, Gastroenterology and Rheumatology patients treated with the listed medications, for any disease, during the period 1 May to 31 July 2025.

Where the figures in the table have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

<b>Drug Name</b>	<b>Dermatology</b>	<b>Gastroenterology</b>	<b>Rheumatology</b>
Adalimumab	99	143	280
Apremilast	9	0	30
Bimekizumab	*	0	0
Brodalumab	*	0	0
Certolizumab Pegol	*	0	35
Deucravacitinib	0	0	0
Etanercept	*	0	176
Etrasimod	0	0	0
Filgotinib	0	10	7
Golimumab	0	0	29
Guselkumab	*	0	0
Infliximab (Biosimilars)	0	97	8
Infliximab (Remicade)	0	0	0
Ixekizumab	0	0	9
Mirikizumab	0	*	0
Ozanimod	0	*	0
Risankizumab	30	72	*
Secukinumab	36	0	54

Tildrakizumab	*	0	0
Tofacitinib	0	*	5
Upadacitinib	12	57	26
Ustekinumab	26	117	12
Vedolizumab	0	129	*